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Abstract
Background: Clinical practice guidelines recommend that the initial treatment of acute low back pain (LBP) should
consist of advice to stay active and regular simple analgesics such as paracetamol 4 g daily. Despite this
recommendation in all international LBP guidelines there are no placebo controlled trials assessing the efficacy of
paracetamol for LBP at any dose or dose regimen. This study aims to determine whether 4 g of paracetamol daily
(in divided doses) results in a more rapid recovery from acute LBP than placebo. A secondary aim is to determine
if ingesting paracetamol in a time-contingent manner is more effective than paracetamol taken when required
(PRN) for recovery from acute LBP.
Methods/Design: The study is a randomised double dummy placebo controlled trial. 1650 care seeking people
with significant acute LBP will be recruited. All participants will receive advice to stay active and will be
randomised to 1 of 3 treatment groups: time-contingent paracetamol dose regimen (plus placebo PRN
paracetamol), PRN paracetamol (plus placebo time-contingent paracetamol) or a double placebo study arm. The
primary outcome will be time (days) to recovery from pain recorded in a daily pain diary. Other outcomes will be
pain intensity, disability, function, global perceived effect and sleep quality, captured at baseline and at weeks 1, 2,
4 and 12 by an assessor blind to treatment allocation. An economic analysis will be conducted to determine the
cost-effectiveness of treatment from the health sector and societal perspectives.
Discussion: The successful completion of the trial will provide the first high quality evidence on the effectiveness
of the use of paracetamol, a guideline endorsed treatment for acute LBP.
Trail registration: ACTRN12609000966291.
Background
Low back pain is common and expensive. The point
prevalence is reported to be as high as 33% [1] and 50%
of people who have low back pain are expected to seek
care [2]. More than AU$1 billion is spent each year on
treatments, while indirect costs to Australian society are
greater than AU$8 billion per annum [3]. In the United
States, the figure is over US$50 billion[4]. Despite the
large number of trials investigating treatments for low
back pain, few treatments have demonstrated better
outcome for patients compared to first line care
endorsed in clinical practice guidelines [5].
Clinical practice guidelines aim to provide the practi-
tioner with evidence-based recommendations upon
which to base patient management. Such guidelines for
acute low back pain have been published in over
11 countries and provide clear agreement on the recom-
mendations for first line care of acute low back pain [6].
According to most guidelines first line care should con-
sist of reassurance on the favourable prognosis of non-
specific low back pain, advice to stay active and avoid
bed rest, and simple analgesic medication recommended
on a time-contingent dose regimen, eg 1 g paracetamol
administered 4 times per day. The provision of more
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patient does not respond to first line care.
Despite broad development and publication of clinical
practice guidelines for low back pain worldwide, usual
care provided to patients appears to be dissimilar to the
evidence-based recommendations [7-12]. A common
finding is that non-steroidal anti-inflammatory drugs are
used in preference to paracetamol for pain relief. While
guidelines recommend regular doses of paracetamol (4 g
daily in divided doses), another common finding is that
when paracetamol is recommended the dose is often
sub-therapeutic or it is administered as required (pro re
nata, PRN), rather than on a time contingent basis [11].
A possible reason for why paracetamol is often not pre-
scribed and/or not used as recommended is that the use
of paracetamol for acute low back pain at any dose has
no direct evidence supporting its effectiveness [5,13,14].
Guideline recommendations to use paracetamol as first
line care thus stem from the relatively low risk of side
effects it presents with comparable benefits when com-
pared to other analgesics [6,15].
Hancock et al [16] showed that adding treatments (non
steroidal anti-inflammatory drugs or spinal manipulative
therapy) to guideline recommended first line care, for
patients with acute low back pain, did not improve
patient outcomes. Although the study does not provide
direct evidence for the efficacy of paracetamol, it found
that patients who received 4 g of paracetamol daily (in
divided doses) recovered rapidly: approximately 50% of
the patients had completely recovered within 2 weeks
and 75% within 4 weeks. These rates are faster than pre-
viously reported in the literature [17,18] and suggest that
an analgesic regimen as simple as 4 g per day of paraceta-
mol may be a highly effective treatment for acute low
back pain. However, without direct evidence for the effi-
cacy of paracetamol in low back pain, it may continue to
be overlooked as a credible treatment.
The primary aim of this study is to investigate
whether taking paracetamol results in faster recovery
times when compared to placebo for patients with acute
low back pain. Further, because guidelines recommend
that adequate, regular doses of paracetamol need to be
administered, this study will also investigate if taking
paracetamol as a time-contingent dose regimen results
in more rapid recovery than taking paracetamol PRN
for pain. Secondary aims of this study are to assess the
effect of paracetamol on pain, disability, global perceived
effect and sleep quality. To help establish the place of
paracetamol in managing acute low back pain this study
we will also conduct a cost-effectiveness analysis of
paracetamol for low back pain and will determine
whether specific variables influence a patient’sr e s p o n s e
to treatment.
Methods/Design
The study will be a three arm randomised double
dummy, placebo controlled trial. Ethics approval has
been obtained from the University of Sydney Human
Research Ethics Committee.
Study Population
O n et h o u s a n ds i xh u n d r e da n df i f t yp e o p l ef r o mt h e
community who consult a general practitioner (GP)
with acute non-specific low back pain will be recruited.
To be eligible to enter the trial all participants must
satisfy the following criteria:
▪ Primary complaint of pain in the area between the
12
th rib and buttock crease, with or without leg pain;
▪ Experiencing a new episode of low back pain, pre-
ceded by a period of at least one month without low
back pain;
▪ Pain of less than 6 weeks duration (in accordance
with the Cochrane Collaboration Back Review
Group definition for ‘acute’ pain)[19];
▪ Low back pain severe enough to cause moderate
pain (as measured by adaptations of item 7 of the
SF-36);
▪ Not have known or suspected serious spinal
pathology (eg metastatic, inflammatory or infective
diseases of the spine, cauda equina syndrome, spinal
fracture);
▪ Not be currently taking recommended regular
doses of analgesics, including paracetamol;
▪ Not have had spinal surgery within the preceding
6 months;
▪ Not have serious co-morbidities preventing pre-
scription of paracetamol eg: liver or renal failure;
▪ Not currently taking psychotropic medication and
whose health condition is considered to prevent reli-
able recording of study information;
▪ Not be pregnant or planning to become pregnant
during the treatment period.
Randomisation and Blinding
Eligible patients will be randomised to one of three treat-
ment groups. Randomisation will be performed in the
following manner. A researcher not involved in patient
recruitment or data collection will create the randomisa-
tion schedule by using the random number function in
EXCEL. An independent company will then prepare the
treatment packs using the randomisation schedule and a
researcher not involved with data collection will cross
check the intended ingredients of a random sample of
the treatment packs to the randomisation schedule to
ensure no errors have occurred.
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the trial the patient will be supplied with a pre-rando-
mised, treatment pack containing the study medicines.
A researcher will then contact the eligible patient to
reconfirm the patient’s eligibility and then instruct them
to break the seal on the randomised medication box.
This contact will occur within 24 hours, where possible,
but no longer than one week from the time of recruit-
ment. After the eligibility criteria are confirmed and the
seal on the medication box has been broken, the patient
will be considered to have been randomised to the trial.
Each treatment pack will contain four coloured medi-
cine boxes (two red and two white). Red boxes are for
medicines to be taken on a time-contingent basis and
white boxes are for PRN medicines. The active medica-
tion differs between each group as follows:
1. Active time-contingent group (Active red pack
and placebo white pack);
2. Active PRN group (Placebo red pack and active
white pack);
3. Placebo group (Placebo red pack and placebo
white pack).
The placebo tablet used in this study is identical to
the active tablet but does not contain the active ingredi-
ent (paracetamol). All medication packaging is identical
with a randomised number printed on the sealed outer
box. The GP, participant and researchers involved in
data collection will be blind to group allocation. To
assess adequate blinding of treatment allocation partici-
pants will be asked at Week 12 if they believed they
took an active time contingent medicine, an active PRN
medicine or two placebo medicines.
Treatments
Participating GPs will be trained on study methods and
procedures individually or in small groups. Specifically,
GPs will be trained in administering the study treatment
(paracetamol and standard advice as recommended in
international evidence based guidelines for acute low
back pain [5,6]).
GPs will be provided with a manual outlining the
study procedures and worksheets for participant recruit-
ment (participant screening checklist, ineligible patient
log, treatment checklist and forms for informed
consent).
All participants will be given advice (to avoid bed rest
and stay active) and reassurance of a favourable prog-
nosis by their GP [6]. In addition, all participants will be
asked to take medications from both the red (time-con-
tingent) and white (PRN) packs. Table 1 shows group
medication scheduling. Participants will receive only one
active medication and therefore a maximum of 4 g of
paracetamol daily as recommended by the Australian
Medicines Handbook (2008). Each active time-contin-
gent dose regimen contains 665 mg of extended release
paracetamol tablets. The instructions for the time-con-
tingent medications will be to take two tablets three
times daily (TID), morning, noon and evening. There-
fore, participants in the active time-contingent group
will receive 3990 mg of paracetamol per day. Each active
PRN tablet will contain 500 mg of immediate release
paracetamol. The instructions for the PRN medications
will be to take 1-2 tablets as required for pain to a max-
i m u mo f8t a b l e t sp e r2 4h o u r s .P a r t i c i p a n t si nt h e
active PRN group will therefore take up to 4 g of para-
cetamol per day. The participants in the placebo group
will receive two inactive (placebo) tablets, identical to
the active medication but containing no paracetamol.
All patients will be asked to continue taking the medi-
cines (active or placebo) until they have experienced
seven consecutive days of pain rated 0 or 1 out of 10 on
a numerical rating scale, or for a maximum of 4 weeks.
Co-interventions
Participants will be asked to return to their GP for
review 1 week after randomisation and not to receive
any other treatments for their back pain. Participants
who experience high levels of continuing or worsening
pain will be able to return to their GP for an earlier
review. Further examination will be provided by the GP
and in some instances, a rescue medication (Naproxen
250 mg) can be provided in addition to the study medi-
cine. The criteria for providing a patient with the rescue
medication will be based on continuing and worsening
pain that is debilitating in nature (in the short term) or
continuing high levels of pain that have not improved
after 7 days of treatment, despite following the advice
and paracetamol regimen. Instructions for the rescue
medication will be to take 2 tablets initially and then 1
tablet every 6 to 8 hours as required for pain relief to a
maximum of 5 tablets in 24 hours. Participants will be
provided with rescue medication for 2 days duration.
The study will record any additional treatments patients
receive in addition to the advice and paracetamol regi-
men, when they took them and how often.
Baseline Assessment
Baseline data will be collected, by a researcher blind to
group allocation, in a telephone interview, before the
participant starts taking the medications. During the
interview, the researcher will reiterate the advice given
to the participant by the GP and confirm the partici-
pants understanding of the medication instructions. At
baseline, data on socio-economic characteristics, general
health, previous and current history, and psychological
characteristics will be collected (see additional file 1).
Williams et al. BMC Musculoskeletal Disorders 2010, 11:169
http://www.biomedcentral.com/1471-2474/11/169
Page 3 of 6Measures of the participants’ status at baseline include:
▪ numerical pain rating scale (0-10 scale) [20];
▪ condition-specific measure of disability (Roland
Morris Disability Questionnaire, 0-24 scale) [20];
▪ patient-generated measure of function (Patient-
Specific Functional Scale, 0-10 scale) [20];
▪ global perceived effect (-5 to 5 scale) [20];
▪ quality of life (SF 12) [21];
▪ sleep quality (Pittsburgh Sleep Quality Index item
6) [22];
▪ treatment credibility (Credibility Expectancy Ques-
tionnaire) [23].
Follow-up procedure
A researcher blind to the treatment allocation will con-
tact participants weekly for the four-week treatment
period until recovery and, if recovery has not occurred,
every two weeks for the remainder of the three-month
follow up period or until recovery. The researcher will
transcribe the participant’s responses, previously
recorded in their individual assessment manuals, into a
separate manual and into a database.
Outcomes
The primary outcome will be days to recovery, which is
defined in two ways, pain intensity rated as 0 or 1 out
of 10 on a 0-10 numerical rating scale (NRS) for seven
consecutive days or the first day the participant has a
rating of 0 out of 10 on the 0-10 NRS. This will be cap-
tured in a daily pain and medication use diary that par-
ticipants will complete until recovery.
Secondary outcomes are pain, disability, function, glo-
bal perceived effect and sleep quality. These data will be
captured at weeks one, two, four and twelve post rando-
misation. These outcomes will allow us to evaluate the
hypothesised role of regular paracetamol or PRN parace-
tamol in improving the clinical course of acute low back
pain. We will also perform an economic evaluation of
paracetamol treatment. For this purpose, data on quality
of life, health care and community service utilisation
and absenteeism (days of reduced work activity) for the
study period will be collected at baseline, 4 weeks and
12 weeks.
Adherence
Adherence with the study medication treatment will be
assessed in three ways; daily self-recorded medication
intake, counts of returned tablets following the comple-
tion of treatment and a compliance questionnaire (Brief
Adherence Rating Scale)[24] administered at Week 4.
Medication adherence will be encouraged at week 1 and
2 follow-up interviews. Tablet boxes and blister foils will
be labelled with the name of the study and give instruc-
tions for scheduling of the medicine. Participants will be
asked to return all unused tablets for counting at the
end of the treatment period in a reply paid post satchel.
Data Integrity and analysis
The integrity of trial data will be monitored by regularly
scrutinising data files for omissions and errors. All data
will be double entered and thes o u r c eo fa n yi n c o n s i s -
tencies will be explored and resolved. For the primary
outcome (days to recovery) we will cross check docu-
ments transcribed by researchers in follow up interviews
with participant diaries returned with the unused medi-
cations. If there is discrepancy, the diaries will be used
as the source data. Where participant documents are
not returned, data transcribed by researchers will be
considered source data.
Data will be analysed by a statistician who is blinded
to group status. The primary analyses will be by inten-
tion-to-treat and we will restrict the number of analyses
in order to reduce the possibility of Type I errors. For
primary outcomes, a p-value of < 0.05 will be considered
statistically significant. For the secondary outcomes a p-
value of < 0.01 will be considered significant.
Primary Statistical Analysis
The difference in survival curves (days to recovery from
pain) will be assessed for the three groups using the
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Page 4 of 6log-rank statistic. The median days to recovery will be
used to express the time to recovery for the three
groups. Cox regression will be used to assess the effect
of treatment group on hazard ratios after allowing for
baseline pain scores, number of previous episodes and
duration of episode as covariates.
Secondary Statistical Analysis
Linear models will be used to assess the effect of treat-
ment group on secondary outcomes at one, two, four
and twelve weeks. Specific comparison will be the effect
of time contingent paracetamol on secondary outcome
measures (pain intensity, disability, function, GPE and
sleep quality) compared to PRN paracetamol or placebo.
A cost-utility analysis will be conducted. The primary
analysis will be conducted from the health sector’sp e r -
spective, where costs of healthcare services will be
valued at standard rates published by the Australian
Government: the Medical Benefits Scheme standard fees
for medical services and procedures, the Pharmaceutical
Benefits Scheme cost for medications and the Australian
Refined Diagnosis Related Groups (AR-DRG) cost
weights for hospital services. Private non-medical
healthcare services (e.g. physiotherapy) will be valued at
standard rates published by the relevant professional
body or third party payer.
A secondary analysis will entail a societal perspective
in which costs associated with the use of community
services and absenteeism will be included. Costs of com-
munity services will be based on the self-reported costs
of participants. The costs of absenteeism from paid
employment will be estimated by the number of days
absent from work multiplied by the average wage rate.
Health state utilities required to estimate quality-
adjusted life-years (QALY) will be based on measures
obtained from the SF-12 and transformed into health
state utilities via the SF-6D algorithm[21]. Sensitivity
analysis will test uncertainty in key parameters such as
the selection of cost weights and statistical variation in
quality of life scores.
A secondary analysis to identify predictors of poor
outcome in patients receiving guideline based first line
treatment (regular paracetamol and advice) will be
performed within treatment arm one (time-contingent
paracetamol). We will also analyse potential effect
modifiers to paracetamol treatment. For this analysis
we will investigate interactions between the potential
effect modifiers and allocation to time-contingent
paracetamol or placebo groups using methods similar
to that used by Hancock et al [25]. A prospective vali-
dation of a published prognostic rule for rate of
recovery from acute low back pain will also be per-
formed [26].
Sample Size
The sample size was calculated using ACCorD software
(version 2). We calculated that a sample size of 550 par-
ticipants per group will give 80% power to detect a dif-
ference of 3 days median time to recovery between the
treatment groups and the control group. These calcula-
tions are based upon the median days to recovery being
14 in the time-contingent paracetamol group, a rate
observed previously [16] and allow for up to 10% treat-
ment non-compliance and a two side alpha of 0.05.
Discussion
This paper presents the design and rationale for a ran-
domised placebo controlled trial examining the effect of
paracetamol on the recovery of patients with acute low
back pain. The trial will also determine if paracetamol
administered as a time-contingent dose regimen is more
effective than paracetamol administered PRN. The pri-
mary outcome will be days to recovery. Secondary out-
comes will be pain, disability, global perceived effect and
sleep quality measured at 1 week, 2 weeks, 4 weeks, and
3m o n t h s .W ew i l lp e r f o r masecondary analysis to
determine the cost-effectiveness of treatment and pre-
dictors of outcome. The completion of this trial is
expected by 2012.
Additional material
Additional file 1: Items measured at baseline assessment. The file
lists items measured at baseline, detailing the wording of the questions
asked, the responses and a source of reference.
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